Wednesday, February 5, 2014

Researchers working to develop new drugs for the treatment of chronic inflammatory diseases

Tags

Researchers working to develop new drugs for the treatment of chronic inflammatory diseases -

Science and industry work together to develop pharmaceuticals for the coming treatment of chronic inflammatory diseases. The drugs will fight against the immunological processes that have gone awry.

Statistics show that there are 300 million people with asthma worldwide, 0 million more people living with chronic pneumonia and up to 30% of the world population by supporting rhinitis allergic (allergic inflammation of the nasal airways). chronic inflammatory diseases may also affect other organs and parts of the body beyond the respiratory system; they can occur in the intestine (in the form of inflammatory bowel diseases such as ulcerative colitis), joints (rheumatoid arthritis), skin (scleroderma), or heart and blood vessels (arteriosclerosis). What each form of inflammatory disease has in common is that it comes from inflammation centers in the body that are prevented from healing by immunological processes that have gone awry.

This is where a new product manufactured by the Canadian company Nuvo Research Inc. comes in. It is already approved for use in many countries worldwide as a medicine to help the local healing, and Thailand is already punishable as a means to treat a variety of chronic diseases. Scientists at the Fraunhofer Institute for Cell Therapy and Immunology IZI in Leipzig to work now with a German subsidiary of the company Nuvo Research GmbH, and the Translational Centre for Regenerative Medicine at TRM Leipzig University to develop a platform that will enable them to better understand how the substance works. Their goal is to optimize the drug to make it easier to administer and better tolerated. Above all, scientists are eager to develop drug compounds with which it might be possible to mitigate an even wider range of chronic diseases, and prepare the products for approval in the European and Canadian markets. The cooperation project sponsored to the tune of 4.4 million euros, should be completed in June 2014.

regeneration process disrupted in the case of chronic inflammation

"L inflammation is the body's response emergency, but inflammation usually begins to decline when it starts. for the body to calm down and stabilize the immune system is temporarily suppressed. suppresses the body defense mechanisms until the inflamed tissue was able to resume its normal functions. this regeneration process is disrupted in the case of chronic inflammation, "says Professor Jürgen Arnhold, who is based in the Faculty of medicine from the University of Leipzig and also conducts research at TRM. Various complications may occur, such as infections and bacterial or fungal disturbances in the healing process. If such complications develop beyond a certain threshold, the immune system will suddenly jump back into the very violent action. It is this interaction between immunosuppression and immune overreaction that scientists are looking into the project. There is clearly a class of enzymes at work that would normally be activated by immune cells in a very specific time. If this activation occurs in an uncontrolled manner, the last phase of the inflammatory process is interrupted and becomes chronic. This is especially when the little low molecular weight substance, developed by Nuvo in: "The studies we have conducted on isolated immune cells indicate that it should be possible to alter the function of certain enzymes involved," said Professor Arnhold.

When scientists TRM studying how immune cells respond to selected drug in Canada, IZI's researchers are interested in examining its effect on the body as a whole. The result of these investigations is that, for the drug to be approved in Europe and North America, the authorities require complex and time-consuming studies to be conducted in its safety, tolerability and efficacy. "We are testing the drug on mice that have the same kinds of symptoms that patients with chronic inflammatory diseases," says Dr. Franziska Lange, responsible for inflammation and Immunodiagnostics unit models IZI. " my work group focuses on three conditions: .. asthma, lung and scleroderma smoker, a disease of autoimmune connective tissue We have 20 different model systems with which we are able to simulate different aspects of Crohn This allows us to record the effects and side effects of different doses of the drug on mice. We see ourselves as a service unit and offer many ways to perform preclinical testing of potential drugs, "she goes on to explain. Three other IZI working groups are testing the drug on mice that have suffered a stroke or who colitis to see if the symptoms of the animals better. They are also investigating whether the drug could be useful in breast cancer treatment.

the three cooperation partners have already conducted two studies and both proved the efficacy and safety of the basic active ingredient. currently, they hope to develop another project to improve drug application method. in Thailand it is currently administered by infusion, which means that patients have to travel to the clinic five days later for several hours at a time. the trio worked on the preparation of the drug in such a way that it can also be injected by family physicians.


EmoticonEmoticon